AI Article Synopsis
- The article from Wien Klin Wochenschr published in 2018 had a mistake in Table 1, leading to inconsistencies.
- A corrected version of Table 1 is now provided.
- The authors apologize for any inconveniences caused by this error.
Article Abstract
Correction to:Wien Klin Wochenschr 2018 https://doi.org/10.1007/s00508-018-1365-5 The original version of this article unfortunately contained a mistake. Table Nr. 1 was inconsistent. The corrected version of Table 1 is given below. We apologize for any inconveniences this may have ….
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828473 | PMC |
| http://dx.doi.org/10.1007/s00508-018-1428-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Bone Marrow Transplant
January 2025
EBMT Transplant Complications Working Party, Paris, France.
Article Synopsis
- The text mentions that there is a correction to the original article indicated by the DOI 10.1002/jha2.854.
- This suggests that there were errors or inaccuracies in the published material that need to be addressed.
- The correction aims to provide accurate information for readers and maintain the integrity of the research presented in the original article.
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.
J Transl Med
June 2024
Department of Pediatrics, Division of Stem Cell Transplantation and Immunology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
Drugs
June 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF.
J Clin Immunol
April 2024
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
Article Synopsis
- * Ruxolitinib treatment led to a significant reduction in the overexpression of inflammatory genes, particularly those related to interferon, improving the patient's autoimmune symptoms.
- * Despite these improvements, epigenetic analysis indicated persistent accessibility of the gene regions associated with inflammation, suggesting that ruxolitinib did not fully correct the underlying epigenetic abnormalities even after treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!